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No correlation was found between maternal methadone dose and rate of neonatal abstinence 
syndrome among 388 neonates exposed to doses up to 340 mg/day. 
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OBJECTIVE:  To estimate the relationship between maternal methadone dose and the incidence 
of neonatal abstinence syndrome (NAS). 
 
METHODS:  We performed a retrospective cohort study of pregnant women treated with 
methadone for opiate addiction who delivered a live-born neonate between 1996 and 2006.  Four 
dose groups, based on total daily methadone dose, were compared (≤80mg/d, 81–120mg/d, 121–
160mg/d, and >160mg/d).  The primary outcome was treatment for NAS.  Symptoms of NAS 
were objectively measured using the Finnegan scoring system and treatment was initiated for a 
score of >24 during the prior 24 hours.   
 
RESULTS:  330 women treated with methadone and their 388 offspring were included.  
Average methadone dose at delivery was 116.6 ±49.7mg/d (range 20-340mg/d).  Overall, 68% of 
infants were treated for NAS.  Among infants exposed to methadone doses of ≤80mg/d, 81–
120mg/d, 121–160mg/d, and >160 mg/d, treatment for NAS was initiated for 68%, 63%, 70%, 
and 73% of neonates, respectively (p=0.48).  The rate of maternal illicit opiate abuse at delivery 
was 26%, 28%, 19%, and 11%, respectively (p=0.04). 
 
CONCLUSION:  No correlation was found between maternal methadone dose and rate of NAS.  
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Methadone has been employed since the early 1970s to treat opiate addiction, and it 
currently remains the standard treatment for opiate addiction in pregnancy.(1)  Benefits of 
methadone include a reduction in cravings for heroin and drug seeking behavior, which thereby 
also reduces the risk of infection with hepatitis C virus and human immunodeficiency virus 
(HIV), prostitution, and criminal activity.(2)  Methadone treatment also protects the fetus from 
repeated episodes of withdrawal by providing steady maternal opiate levels.(3)  Furthermore, 
comprehensive methadone maintenance programs provide opiate-addicted women with the 
opportunity to receive essential prenatal care and services that they would otherwise be 
without.(4)  Despite these benefits, methadone treatment is not without controversy, and much of 
the debate centers on the optimal methadone dose and on its association with neonatal abstinence 
syndrome (NAS). 
One of the earliest reports of the relationship between methadone and neonatal 
withdrawal was published in 1975 by Rosen et al. The authors found no consistent relationship 
between maternal methadone dose and the severity of neonatal withdrawal symptoms in this 
study and a subsequent study in 1976.(5)(6)  In the same year, several studies reported the 
opposite, showing a positive correlation between maternal methadone dose and both the severity 
of neonatal withdrawal symptoms and the incidence of neonatal withdrawal requiring 
pharmacologic treatment with maternal methadone doses < 20 mg/d.(7)(8)(9) Of eight published 
studies, to our knowledge, which include a “low” dose group of < 30 mg/d 78% report a positive 
correlation between maternal methadone and NAS.(6)(7)(8)(9)(10)(11)(12)(13)  Presently, 
methadone maintenance programs for pregnant women, such as ours, use significantly higher 
doses to prevent withdrawal.  Five out of six (83%) more recent published studies which use a 
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higher cutoff (< 50 mg/d or above) to define the “low” dose group report no such 
association.(14)(15)(16)(17)(18)(19) Yet, despite these and other studies 
(20)(21)(22)(23)(24)(25) there is still no clear answer.  Much of difficulty is due to the 
considerable methodological variability such as the inclusion of women undergoing withdrawal 
treatment as opposed to maintenance, insufficient reporting of confounding factors (i.e. 
polysubstance abuse), and differences in the definition and assessment of NAS (Table 1; online 
only).  With these limitations in mind, our objective was to estimate the relationship between 
clinically appropriate methadone doses and NAS.  
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MATERIALS AND METHODS 
We performed a retrospective review of the outcomes of opiate-addicted women on 
methadone maintenance who delivered a live-born neonate between September 1996 and June 
2006.  A full description of our approach to methadone stabilization and maintenance has been 
previously described elsewhere.(14)  The only change in maternal management over the eleven 
year study period was a small increase (20mg to 30mg) in the initial stabilization dose.  There 
were no changes in neonatal assessment or treatment for NAS.  No distinction was made 
between women who conceived while already enrolled in a methadone program and those who 
became pregnant while on heroin and required initial stabilization during pregnancy.   
All neonates were delivered at Thomas Jefferson University Hospital.  We excluded 
infants delivered < 32 weeks gestation, as signs and symptoms of prematurity can be confused 
with NAS.(21)  Non-viable fetuses delivered before 23 weeks gestation and stillbirths were also 
excluded.  Signs and symptoms of NAS were objectively assessed every eight hours for the first 
72 hours of life according to the method described by Finnegan.(25)  Treatment for NAS was 
initiated for a cumulative score ≥ 24 during the prior 24 hours.  The NAS treatment protocol at 
our institution has been described elsewhere.(26)  Data for a portion of the women and neonates 
has been previously reported.(14)(26) 
Exposure to methadone was confirmed by a UDS for methadone.  For women who 
instead had a drug of abuse screen (does not test for methadone), documentation in the medical 
record of methadone use was necessary for inclusion in the study.  The methadone dose at 
delivery was defined as the total daily methadone dose at the time of delivery.  To determine the 
cohorts, we divided women into four dose groups approximating quartiles; ≤ 80 mg/d, 81 – 120 
mg/d, 121 – 160 mg/d, and > 160 mg/d.  A receiver operator characteristic (ROC) curve was 
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used to determine the sensitivity and specificity of various methadone dose cutoffs for predicting 
NAS ensuring the appropriateness of these dose groups. 
All statistical tests were performed with SPSS 17.0 (SPSS Inc., Chicago, IL).  The χ2 test, 
analysis of variance test, and Kruskal-Wallis test were used to analyze categorical, normally 
distributed continuous, and non-normally distributed continuous variables, respectively.  A p 
value < .05 was considered statistically significant.  Several women delivered twice during the 
study period.  To adjust for potential confounding and clustering due to women who had more 
than one pregnancy during the study period, a generalized estimating equation model was used.  
For women who delivered after 2000, the database was expanded to include additional 
variables.  The additional information gathered included non-opiate illicit drug abuse at delivery 
as determined by urine drug screen (UDS), selective serotonin reuptake inhibitor use, alcohol use 
(by self report), and others.  Due to the difference in the amount of variables, two separate 
multivariate models were fit.  The first was termed "limited" in time as it included a larger set of 
variables which were recorded only for women who delivered between January 2000 and June 
2006.  The second was deemed “extended" in time as it included fewer variables, but data was 
available for all women who delivered during the entire 10 year study period (September 1996 
and June 2006).  For both the “limited” and "extended" adjustments, variables with p < 0.2 found 
through univariate analysis were included as covariates in the generalized estimating equation 
model to calculate adjusted odds ratios (OR) with 95% confidence intervals (CI).  This study was 
approved by the Thomas Jefferson University Institutional Review Board.   Informed consent 





We analyzed outcomes of 330 opiate-addicted women on methadone treatment who had 
386 pregnancies from September 1996 to June 2006.  Two women had twins, thus our study 
included 388 neonates.  The gestational age at birth was < 32 weeks for 19 neonates (range 27-31 
weeks) excluded from the study.  Maternal demographic characteristics are presented in Table 2.  
Only race differed among dose groups (p = .04).  Caucasian women were on higher mean doses 
of methadone (122.9 ± 50.7 mg/d) when compared to non-Caucasian women (103.5 ± 44.9 mg/d, 
p < .001).  Psychiatric medications were prescribed to 27% of women in the methadone 
maintenance program and 23% of those women were taking more than one psychiatric 
medication (data available for 288 pregnancies).  The proportion of women in each dose group 
using prescription psychiatric drugs was not significantly different (p = .39) but prescription 
benzodiazepine use (mainly clonazepam) was more common among women on higher doses (p = 
.01).  
Table 3 presents details of the methadone maintenance program and rates of illicit 
substance abuse at the time of delivery.  Overall, the average methadone dose at delivery was 
116.6 mg/d (range 20-340 mg/d).  Timing of methadone stabilization (before or during 
pregnancy) and rate of re-stabilization (due to non-compliance) was known for 288 pregnancies.  
Women who conceived on methadone had a higher mean methadone dose at delivery compared 
to those who were stabilized during pregnancy (135.3 ± 55.5 mg/d vs. 118.5 ± 48.7 mg/d; p = 
.01) and a greater proportion of women who conceived on methadone were in higher dose 
groups.  Admissions for re-stabilization were less likely in the higher dose groups as was illicit 
opiate abuse.  Of the 77 women with known prescription psychiatric medication use, 27 (35%) 
used illicit drugs at delivery compared to 42 (20%) of the 211 not taking prescription psychiatric 
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medications (p = .008).  Women who were initially stabilized on methadone during pregnancy 
had lower rate of illicit drug abuse at delivery (66 [34%] vs. 26 [28%]; p = .36) and illicit opiate 
abuse at delivery (11 [12%] vs. 36 [18%]; p = .17) but the difference did not reach statistical 
significance. 
Neonates had an average gestational age at delivery of 37.7 ± 2.2 weeks.  .  The rate of 
preterm birth (≥ 32 weeks and < 37 weeks) was 27% (106/388).  The mean birth weight and head 
circumference were 2808 ± 544 g and 32.5 ± 2.1 cm, respectively.  No significant differences 
were found between gestational age at delivery, birth weight, head circumference, and rate of 
preterm birth among neonates exposed to maternal methadone doses of ≤ 80 mg/d, 81 – 120 
mg/d, 121 – 160 mg/d, and > 160 mg/d (all p > .31).   
 Indices of NAS according to maternal methadone dose are included in Table 4.  Overall, 
262 (62%) neonates required treatment for NAS.  There was no significant difference in the 
incidence of NAS, maximum NAS score, length of neonatal treatment, or maximum dose of 
neonatal opium solution between difference dose groups.  Among women who had more than 
one pregnancy during the study period, there was a trend toward higher mean methadone doses 
in the subsequent pregnancy (119 ±51.7 mg/d 1st pregnancy versus 134 ±58.2 mg/d 2nd 
pregnancy; p = .18) however, there was no difference in the rate of NAS (64% 1st pregnancy 
versus 62% 2nd pregnancy; p = .83).  Even after adjusting for confounding by significant 
variables (p <0.2) and the effect clustering due to multiple pregnancies by the same woman, no 
correlation was found between methadone dose and NAS (Table 5; online only).  Additionally, 
no methadone dose defined a cutoff significantly predictive of NAS using a ROC curve (area 
.52; p = .52 [95% CI .46-.58]).  In the < 80 mg/d dose group, only 7 women had a methadone 
dose at delivery that was < 30 mg/d.  In this subgroup, four (57%) neonates were treated for NAS 
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for 7, 30, 31, and 54 days.  Compared to women on higher doses, there was no significant 
difference in the rate of NAS (p= 1.0).  The Figure depicts the stable rate of NAS against the 
reduction in illicit opiate abuse at delivery which is most apparent in the three highest dose 
groups (Figure). 
 The rate of NAS was compared between methadone dose groups for selected 
subpopulations of women (Table 4).  NAS was more common among neonates born to women 
who were initially stabilized on methadone during pregnancy but the difference was not 
statistically significant (p = .18).  There was no difference in the incidence of NAS between 
methadone dose groups for either neonates born to women who conceived on methadone or 
those who were born to women initially stabilized on methadone during pregnancy.  Likewise, 
these was no difference in the incidence of NAS between dose groups for the subpopulations of 
women abusing illicit opiates at delivery, women whose UDS was negative for illicit opiate 
abuse at delivery, women who delivered prematurely, and those who delivered at term.   
Lastly, we also investigated other variables predictive of NAS (Table 6; online only).  
Through a univariate analysis, preterm birth, tobacco use, and illicit opiate and cocaine abuse at 
delivery increased the risk for NAS (Table 5; online only).  However, after adjusting for 
confounding, only preterm birth (adjusted OR 3.0, 95% CI 1.4 – 6.1) remained predictive of 






The incidence of NAS in our population was 68% and is well within the literature's 
reported range of 30% to 81%.(9)(22)  Even among neonates born to women prescribed the 
lowest methadone dose, NAS required treatment in more than half of neonates.  In our 
population, the incidence of NAS requiring pharmacologic treatment does not reflect maternal 
methadone use in a dose dependent fashion.  Furthermore, higher doses of methadone were 
associated with decreased maternal illicit opiate abuse at delivery.    
There is strong physiologic evidence to support our policy of liberal dose increases to 
decrease maternal withdrawal symptoms.  First, physiologic changes throughout pregnancy alter 
the pharmacokinetics and pharmacodynamics of methadone. Plasma volume is increased leading 
to an increased volume of distribution.  The fraction of oral methadone absorbed is decreased, 
the half life of methadone decreased (27) secondary to increased hepatic clearance (28)(29), and 
protein binding is decreased.(30)  Additionally, there is a high degree of inter-individual 
variability in methadone metabolism.  Maternal symptomatology more closely reflects serum 
trough level than dose.(31)(32)   
The concentration of methadone crossing the placenta determined by gestational age-
dependent passive diffusion, P-glycoprotein efflux, and metabolism by placental aromatase. 
(33)(34)(35)(36)  The fetal concentration is then modified by hepatic metabolism, a process 
which is also gestational age dependent.  Ultimately, the expression of opioid withdrawal is 
dependent on the final neonatal methadone concentration and its interplay with the central 
nervous system (also gestational age dependent [21]).  Even the exact relationship between 
neonatal methadone levels at birth is unclear (17)(22)(24)(37)(38) and total opioid exposure 
(methadone plus other illicit opiate abuse) should be factored in as a confounder.  Given the 
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complex relationship between the mechanisms that determine neonatal dose and expression of 
NAS, it unlikely an individual woman’s methadone dose will reliably predict neonatal outcome. 
 Most of the women in our study had one or more exposures to tobacco, alcohol, other 
illicit drugs or prescription medications thought to confound the expression and severity of 
withdrawal.  Both Tobacco and benzodiazepines (prescription or illicit) worsen methadone 
withdrawal. (14)(20)(26)(39)(40)(41)(42)(43)  Likewise, abruption discontinuation of cocaine at 
birth results in a neonatal toxicity with symptoms that overlap with methadone 
withdrawal.(39)(44)  The effect of each of these exposures was adjusted for in the statistical 
analysis (Tables 5 and 6). 
 Neonatal withdrawal from selective serotonin reuptake inhibitors (SSRIs) is a well 
recognized syndrome (45)(46) that occurs in 22-31.5% of exposed neonates.(47)  The signs and 
symptoms of SSRI withdrawal overlap considerably with opioid withdrawal and can be 
measured with the Finnegan scoring system.(47)  Additionally, SSRIs may increase methadone 
concentrations through inhibition of the CYP450 system.(48)  While it is possible that SSRI 
withdrawal confounded the assessment of NAS this effect would have caused a small but equal 
increase in the incidence of NAS in each group since there was no significant difference in SSRI 
use.   Other studies have also shown that SSRI use does not increase the odds of receiving 
treatment for NAS (11) or affect the length of treatment.(26)      
A significant strength of our study is the large population size.  The majority of studies 
reporting an association between maternal methadone dose and NAS were small studies that 
included only 70 infants or less.(9)(10)(12)(16)(21)(22)   Also, our population includes women 
prescribed the highest reported doses used in pregnancy.  The lowest dose group, < 80 mg/d, 
may be considered as such compared to studies that used a cutoff of < 30 mg/d.  Since our 
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methadone stabilization protocol uses an initial stabilization dose of either 20 or 30 mg/d and the 
median methadone dose after initial hospital stabilization was 65 mg/d (range 15-250 mg/d)(26 
unpublished data) a “very low” dose group (i.e. < 30 mg/d) would be impractical.  Furthermore, 
the large population size and wide dose range included in our study allowed us to compare the 
rate of NAS between four near-equal sized dose groups inclusive of all previously published cut-
offs, as opposed to just comparing "high" and "low" dose groups as many previous studies have 
done.      
Another important strength of our research was the choice to use NAS requiring 
pharmacologic treatment, based on Finnegan score, as the primary outcome.  The use of an 
objective outcome is especially important since, as in most studies, the neonatologists were not 
blinded to maternal methadone dose.  Instead, other studies chose to use presence or severity of 
withdrawal symptoms (8)(9)(24) or used NAS requiring pharmacologic treatment measured by 
novel scoring systems.  We contend that NAS requiring treatment determined by a recognized 
NAS scoring system (Finnegan [25], Lipsitz [49], Rivers [50]) is the most appropriate outcome 
measure for studying neonatal withdrawal due to in utero methadone exposure.  Most neonates 
experience at least some symptoms of withdrawal but neonates that do not require treatment are 
discharged home after three days as opposed to an average of 30 days when treatment is 
necessary.(26)  Readmission after 72 hours for withdrawal or dehydration is a possibility that 
was not analyzed.  However, of the approximately 30% of neonates who are discharged without 
treatment for NAS and whose mothers are following up at the Family Center methadone 
treatment program, readmission is rare according to the neonatologists (Dysart) at our hospital.   
 This study evaluated the outcomes of neonates delivered over an 11 year period.  
Although practice changes over time, save for a marginal difference in the initial methadone 
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stabilization dose (20 mg/d (14) versus 30 mg/d (26), there were no other changes in either 
maternal or neonatal management during that interval.  Another limitation is the expansion of the 
type and amount of data included in the database.   Consistency in the data collected over the two 
periods was verified by carefully comparing the data dictionaries from both periods.  We did not 
consider the effect of breastfeeding, as such data was unavailable.  The importance of 
breastfeeding in preventing NAS remains controversial.(11)(16)(40)(51)  The concentration of 
methadone in breast milk is low (52) and although the absolute concentration is dose dependent, 
is unlikely to be sufficient to prevent withdrawal.(53) 
  The best measure of the adequacy of methadone treatment is cessation of illicit opiate 
abuse.  In our study, only 11% of women taking > 160 mg/d of methadone also abused illicit 
opiates at the time of delivery versus 27% of women who took ≤ 120 mg/d.  McCarthy et al 
noted similar findings, as only 11% of infants from their high dose methadone group (≥ 100 
mg/d) were positive for illicit drugs compared to 27% of infants from their low dose group (< 
100 mg/d).(18)  The benefits of methadone maintenance include cessation of illegal activities, 
avoidance of infectious diseases, and participating in prenatal care.  Therefore, preventing 
continued drug abuse by providing therapeutic doses would seem far more important than using 
low methadone doses to theoretically reduce the incidence of NAS, which when treated 
appropriately has not been demonstrated to have any untoward effects.(3) 
Our findings provide compelling evidence that no correlation exists between maternal 
methadone dose and rate of NAS.  Reducing maternal methadone doses to theoretically lower the 
risk for NAS appears unwarranted.  Instead, the goal of the clinician should be to administer 
doses of methadone that adequately control maternal withdrawal symptoms and reduce drug 
cravings.  In the future, a randomized, double blinded study to validate our results in which in 
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one group women are restricted to a certain dose while the ones in the other group aren’t would 
be ideal.  There may be ethical concerns over restricting dose and possibly subjecting both the 
mother and fetus to withdrawal as this would constitute detoxification.  In our opinion, an 
adequately powered prospective trial with both the physician prescribing methadone and the 
pediatrician blinded to dose, an objective measurement of NAS, and controlling for known 
confounders would probably be a viable alternative.  
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